NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 230 filers reported holding NOVOCURE LTD in Q3 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $232,156 | -61.1% | 14,375 | +0.1% | 0.00% | -62.5% |
| Q2 2023 | $596,231 | -29.7% | 14,367 | +1.8% | 0.01% | -33.3% |
| Q1 2023 | $848,395 | -17.4% | 14,107 | +0.7% | 0.01% | -29.4% |
| Q4 2022 | $1,027,047 | +10.6% | 14,002 | +14.5% | 0.02% | -5.6% |
| Q3 2022 | $929,000 | +11.1% | 12,224 | +1.7% | 0.02% | +5.9% |
| Q2 2022 | $836,000 | -13.3% | 12,022 | +3.3% | 0.02% | +6.2% |
| Q1 2022 | $964,000 | +11.6% | 11,639 | +1.2% | 0.02% | +14.3% |
| Q4 2021 | $864,000 | -36.4% | 11,506 | -1.6% | 0.01% | -46.2% |
| Q3 2021 | $1,358,000 | -48.8% | 11,690 | -2.3% | 0.03% | -46.9% |
| Q2 2021 | $2,654,000 | +93.2% | 11,964 | +15.1% | 0.05% | +69.0% |
| Q1 2021 | $1,374,000 | -24.3% | 10,394 | -0.9% | 0.03% | -27.5% |
| Q4 2020 | $1,815,000 | +56.7% | 10,488 | +0.8% | 0.04% | +42.9% |
| Q3 2020 | $1,158,000 | +87.1% | 10,402 | -0.4% | 0.03% | +75.0% |
| Q2 2020 | $619,000 | – | 10,439 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |